The use of sunitinib as maintenance therapy in a pediatric patient with a poorly differentiated thymic carcinoma Journal Article


Authors: Romanos-Sirakis, E.; Doan, A.; Bittman, M. E.; Webb, R. L.; Williamson, A. K.; Edelman, M.; Hanson, D.; Riely, G. J.; Fein Levy, C.
Article Title: The use of sunitinib as maintenance therapy in a pediatric patient with a poorly differentiated thymic carcinoma
Abstract: Background: Thymic carcinomas are rare aggressive mediastinal tumors with a median survival of 2 years. Observation: We present a pediatric patient who was diagnosed with metastatic thymic carcinoma and showed continuous improvement of his primary mass and lung metastases with a regimen of cisplatin/docetaxel followed by long-term maintenance therapy with sunitinib for over 5 years. Conclusions: This report demonstrates a long-term positive treatment effect using chemotherapy followed by sunitinib in an advanced thymic carcinoma. We are not aware of other reports of pediatric patients with metastatic thymic carcinoma treated with sunitinib maintenance who maintained a durable response for this prolonged period of time.
Keywords: sunitinib; chemotherapy; thymoma; thymic carcinoma; epithelial tumors; cohort; tyrosine-kinase inhibitors; rare tumors
Journal Title: Journal of Pediatric Hematology/Oncology
Volume: 44
Issue: 2
ISSN: 1077-4114
Publisher: Lippincott Williams & Wilkins  
Date Published: 2022-03-01
Start Page: E605
End Page: E608
Language: English
ACCESSION: WOS:000760391300080
DOI: 10.1097/mph.0000000000002312
PROVIDER: wos
PUBMED: 34486558
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gregory J Riely
    599 Riely